Faculty profile

Angela Genge

ResearcherNeurology and NeurosurgeryMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Angela Genge

Researcher

Neurology and Neurosurgery

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
72 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2016.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

110

Publications

212

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Amyotrophic Lateral Sclerosis (Als)Csf Enoxacin Mirna Pharmacodynamics Pharmacokinetics Phase 1 Clinical Trial Rare Disease

Latest papers

Safety of Intravenous Edaravone in Clinical Practice.
Muscle & nerve · 2026 · first author
ALS motor phenotypes: a revised 'OPM' classification.
Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026 · senior author
Utility of patient subgrouping in ALS clinical trials: a World Federation of Neurology white paper.
Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026

All 110 publications

Latest funding

Unifying Molecular Omics, Multi-Modal Neuroimaging and Artificial Intelligence for Biologically-defined Patient Stratification in Amyotrophic Lateral Sclerosis
CIHR · 2021 · Co-investigator
$698,064
REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis
CIHR · 2016 · Nominated PI
$256,250
The George Karpati Symposium on Neuromuscular Disease: Innovation and Application
CIHR · 2009 · Co-investigator
$6,465

All 3 grants and awards

110 publications.

Safety of Intravenous Edaravone in Clinical Practice.

Genge A, Apple S

Muscle & nerve2026First author

DOI: 10.1002/mus.70038 PMID: 41653005

ALS motor phenotypes: a revised 'OPM' classification.

Meyer T, Ticozzi N, Weber M, Ravits J, Lingor P, Kuźma-Kozakiewicz M, Boentert M, Grehl T, Corcia P, Povedano Panadés M, Maier A, Ingre C, Cetin H, Weydt P, Lunetta C, van den Berg L, Ludolph AC, Brenner D, Turner MR, Genge A

Amyotrophic lateral sclerosis & frontotemporal degeneration2026Senior author

DOI: 10.1080/21678421.2026.2644277 PMID: 41843813

Utility of patient subgrouping in ALS clinical trials: a World Federation of Neurology white paper.

Rosenfeld J, Abrahams S, McHutchinson C, Ajroud-Driss S, Weber M, Paganoni S, Mitsumoto H, Genge A, Grosskreutz J, Van Den Berg L, Andrews J, Kiernan MC

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2025.2593308 PMID: 41361897

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Miller TM, Cudkowicz ME, Shaw PJ, Genge A, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Salachas F, Bruneteau G, Al-Chalabi A, Amorin M, Nestorov I, Graham D, Lin L, Sun P, McNeill M, Malek S, Inra J, Garafalo S, Fradette S, VALOR and OLE Working Group

JAMA neurology2026

DOI: 10.1001/jamaneurol.2025.4946 PMID: 41661214

The World Federation of Neurology Specialty Group in ALS/MND: toward strategic partnership and new frontiers.

Kiernan MC, Genge A, Grosskreutz J, Kuwabara S, Lillo P, Rosenfeld J, Cummings C

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2026.2663915 PMID: 42060866

Cell-free miRNAs are pharmacodynamic biomarkers for enhanced DICER activity by enoxacin in human patients with ALS.

Magen I, Kaneb HM, Masnata M, Pulimood N, Emde A, Genge A, Hornstein E

Molecular therapy : the journal of the American Society of Gene Therapy2026

DOI: 10.1016/j.ymthe.2026.03.002 PMID: 41792996

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Kim S, Curtis SE, Iacono D, Mehdiyoun NF, Mitchell L, Genge A, Brandt AU, Pooled Resource Open-Access ALS Clinical Trials Consortium, Mancini M

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2026.2667290 PMID: 42160473

Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.

Weemering DN, van Unnik JWJ, Genge A, van den Berg LH, van Eijk RPA

Neurology2026

DOI: 10.1212/wnl.0000000000214937 PMID: 42013406

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

Zaidman CM, Proud C, Liao B, Rad N, Ho D, Chu ML, Ladha S, Crawford TO, Nayar S, Genge A, Frey M, Heatwole C, Lew D

Neuromuscular disorders : NMD2026

DOI: 10.1016/j.nmd.2025.106256 PMID: 41813449

The genetics of autosomal recessive ALS: a review of the common forms and their phenotypes.

Allen MD, Diab V, Lezaic N, Binet M, Gentil BJ, Blanchard O, Genge A, Massie R

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2026.2615110 PMID: 41592170

Something wrong or missing on this profile? Suggest a correction

Angela Genge

Research

Latest papers

Latest funding

Safety of Intravenous Edaravone in Clinical Practice.

ALS motor phenotypes: a revised 'OPM' classification.

Utility of patient subgrouping in ALS clinical trials: a World Federation of Neurology white paper.

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

The World Federation of Neurology Specialty Group in ALS/MND: toward strategic partnership and new frontiers.

Cell-free miRNAs are pharmacodynamic biomarkers for enhanced DICER activity by enoxacin in human patients with ALS.

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials&#xa0;(PRO-ACT) database.

Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

The genetics of autosomal recessive ALS: a review of the common forms and their phenotypes.

Unifying Molecular Omics, Multi-Modal Neuroimaging and Artificial Intelligence for Biologically-defined Patient Stratification in Amyotrophic Lateral Sclerosis

REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis

The George Karpati Symposium on Neuromuscular Disease: Innovation and Application

Frequent collaborators

Lawrence Korngut

Sanjay Kalra

Richard Frayne

Yana Yunusova

Christian Beaulieu

Craig Campbell

Jason Karamchandani

Jason Karamchandani

Marvin Chum

Gerald Pfeffer

Maryam Oskoui

Alan Wilman

John Turnbull

Ekaterina Rogaeva

Richard Frayne

Jodi Warman Chardon

Simon Graham

Benjamin Ritsma

Sanjay Kalra

Jasna Kriz

Janice Robertson

Lorne Zinman

Bernard Brais

Alain Dagher

Angela Genge

Jean-Baptiste Poline

Mahsa Dadar

Janelle Drouin-Ouellet

Andrea Benedetti

Esther Fujiwara

Julien Doyon

Thomas Durcan

Hans Katzberg

Yasser Iturria Medina

Oury Monchi

Mark Tarnopolsky

Ashley Waito

Michel Panisset

Christine Vande Velde

Dean Eurich

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.